- Home
- HDL vs RLAY Comparison
HDL vs RLAY Comparison
Compare HDL & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDL
- RLAY
- Stock Information
- Founded
- HDL 2016
- RLAY 2015
- Country
- HDL Singapore
- RLAY United States
- Employees
- HDL N/A
- RLAY N/A
- Industry
- HDL Restaurants
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HDL Consumer Discretionary
- RLAY Health Care
- Exchange
- HDL Nasdaq
- RLAY Nasdaq
- Market Cap
- HDL 1.2B
- RLAY 1.1B
- IPO Year
- HDL 2024
- RLAY 2020
- Fundamental
- Price
- HDL $27.99
- RLAY $4.46
- Analyst Decision
- HDL
- RLAY Strong Buy
- Analyst Count
- HDL 0
- RLAY 10
- Target Price
- HDL N/A
- RLAY $20.11
- AVG Volume (30 Days)
- HDL 30.7K
- RLAY 2.6M
- Earning Date
- HDL 11-25-2024
- RLAY 11-06-2024
- Dividend Yield
- HDL N/A
- RLAY N/A
- EPS Growth
- HDL N/A
- RLAY N/A
- EPS
- HDL 0.09
- RLAY N/A
- Revenue
- HDL $759,894,000.00
- RLAY $10,006,000.00
- Revenue This Year
- HDL $19.69
- RLAY N/A
- Revenue Next Year
- HDL $14.20
- RLAY N/A
- P/E Ratio
- HDL $310.69
- RLAY N/A
- Revenue Growth
- HDL 16.09
- RLAY N/A
- 52 Week Low
- HDL $13.94
- RLAY $4.25
- 52 Week High
- HDL $30.00
- RLAY $12.14
- Technical
- Relative Strength Index (RSI)
- HDL N/A
- RLAY 40.06
- Support Level
- HDL N/A
- RLAY $4.41
- Resistance Level
- HDL N/A
- RLAY $5.03
- Average True Range (ATR)
- HDL 0.00
- RLAY 0.32
- MACD
- HDL 0.00
- RLAY 0.07
- Stochastic Oscillator
- HDL 0.00
- RLAY 27.17
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).